Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 to 5 (Cancelled).

6 (Previously presented) A tablet formulation according to Claim 16 wherein the core and the casing layer both comprise a compacted mixture of components.

7 (Previously presented). A tablet formulation according to Claim 16 wherein the release retarding coating is an enteric polymer .

8 (Previously presented). A tablet formulation according to Claim 16 further comprising one or more sub-coats beneath the release retarding coating layer.

9 (Previously presented). A tablet formulation according to Claim 16 further comprising one or more over-coats above the release retarding coating layer.

10 to 15 (Cancelled).

16 (Currently amended). A tablet formulation for oral administration comprising amoxycillin and clavulanate in a ratio of 30:1 to 1:1 in which a portion of the amoxycillin and all of the clavulanate is in a central core which is surrounded by a release-retarding coating layer and the remainder of the amoxicillin is in a casing layer surrounding the core, such that there is an initial quick release of amoxycillin and clavulanate from the casing layer and a sustained release of amoxycillin ~~and clavulanate~~ from the core.

17 (Previously presented). A tablet formulation according to Claim 16 for oral administration twice a day.

18 (Previously presented). A method of treating a bacterial infection in a patient in need thereof, which method comprises administering to said patient an effective amount of a formulation according to Claim 16.

19 (Previously presented). A tablet according to claim 7 wherein the enteric polymer is cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinylacetatephthalate, polyvinylbutyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic mono-ester copolymer, methyl acrylate-methacrylic acid copolymer, or methacrylate-methacrylic acid-octyl acrylate copolymer, or a mixture thereof.

20 (Previously presented). A tablet according to claim 19 wherein the enteric polymer coating is a methacrylic acid – methacrylate copolymer.

21 (Previously presented). A tablet according to Claim 7 wherein the enteric polymer further comprises a plasticiser.

22 (Previously presented). A tablet according to Claim 7 wherein the enteric polymer further comprises an anti-foaming agent.

23 (Previously presented). A tablet according to Claim 7 wherein the enteric polymer further comprises an anti-tack agent.

24 (Previously presented). A tablet according to Claim 16 wherein the amoxycillin is amoxycillin trihydrate.

25 (Previously presented). A tablet according to Claim 16 wherein the clavulanate is potassium clavulanate.

26 (Previously presented). A tablet according to Claim 8 wherein the sub-coat is hydroxypropylmethylcellullose.

27 (Previously presented). A tablet according to Claim 9 wherein the over-coat is hydroxypropylmethylcellullose, or a co-polymer of methacrylic acid and methyl methacrylate.

28 (Previously presented). A tablet according to Claim 16 wherein the casing layer is coated with a top coat.

29 (Previously presented). A tablet according to Claim 28 wherein the top coat is hydroxypropylmethylcellulose.

30 (Previously presented). A tablet formulation according to Claim 16 wherein the total weight of amoxycillin is from 25 to 75% in the central core.

31 (Previously presented). A tablet formulation according to Claim 16 wherein the total weight of amoxycillin is from 50 to 75% in the central core.

32 (Previously presented). A tablet formulation according to Claim 16 wherein the total weight of amoxycillin is from 75 to 25% in the casing layer.

33 (Previously presented). A tablet formulation according to Claim 16 wherein the total weight of amoxycillin is from 50 to 25% in the casing layer.

34 (Currently amended). A tablet formulation for oral administration comprising amoxycillin and clavulanate in a ratio of 30:1 to 1:1 in which a portion of the amoxycillin and all of the clavulanate is in a central core which is surrounded by a release-retarding coating layer and the remainder of the amoxicillin is in a casing layer surrounding the core, such that there is an initial quick release of amoxycillin and clavulanate from the casing layer and a delayed release of amoxycillin ~~and clavulanate~~ from the core.

35 (Previously presented). A tablet formulation according to Claim 34 wherein the total weight of amoxycillin is from 25 to 75% in the central core.

36 (Previously presented). A tablet formulation according to Claim 34 wherein the total weight of amoxycillin is from 50 to 75% in the central core.

37 (Previously presented). A tablet formulation according to Claim 34 wherein the total weight of amoxycillin is from 75 to 25% in the casing layer.

38 (Previously presented). A tablet formulation according to Claim 34 wherein the total weight of amoxycillin is from 50 to 25% in the casing layer.

39 (Previously presented). A tablet formulation according to Claim 34 wherein the release retarding coating is an enteric polymer.

40 (Previously presented). A tablet formulation according to Claim 39 further comprising one or more sub-coats beneath the release retarding coating layer.

41 (Previously presented) A tablet according to Claim 40 wherein the sub-coat is hydroxypropylmethylcellullose.

42 (Previously presented). A tablet formulation according to Claim 34 further comprising one or more over-coats above the release retarding coating layer.

43 (Previously presented). A tablet according to Claim 42 wherein the over-coat is hydroxypropylmethylcellullose, or a co-polymer of methacrylic acid and methyl methacrylate.

44 (Previously presented). A tablet according to Claim 34 wherein the casing layer is coated with a top coat.

45 (Previously presented). A tablet according to Claim 44 wherein the top coat is hydroxypropylmethylcellulose.

46 (Previously presented). A tablet according to Claim 45 wherein the enteric polymer is cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinylacetatephthalate, polyvinylbutyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic mono-ester copolymer, methyl acrylate-methacrylic acid copolymer, or methacrylate-methacrylic acid-octyl acrylate copolymer, or a mixture thereof.

47 (Previously presented). A tablet according to claim 46 wherein the enteric polymer is a methacrylic acid – methacrylate copolymer.

48 (Previously presented). A tablet according to claim 39 wherein the enteric polymer further comprises a plasticiser.

49 (Previously presented). A tablet according to claim 39 wherein the enteric polymer further comprises an anti-foaming agent.

50 (Previously presented). A tablet according to Claim 39 wherein the enteric polymer further comprises an anti-tack agent.

51 (Previously presented). A tablet according to Claim 34 wherein the amoxycillin is amoxycillin trihydrate.

52 (Previously presented). A tablet according to Claim 34 wherein the clavulanate is potassium clavulanate.

53 (Previously presented). A tablet formulation according to Claim 34 for oral administration twice daily.

54 (Previously presented). A method of treating a bacterial infection in a patient in need thereof, which method comprises administering to said patient an effective amount of a formulation according to Claim 34.